ArticleScientific reports2025
Risk factors for multidrug resistant and carbapenem resistant Pseudomonas aeruginosa bloodstream infections among inpatients in Central and East China.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Pathogen characteristics and pre-index clinical factors associated with multidrug-resistant organism infections in intensive care unit patients.Frontiers in public health · 2026Observational
- Clinical gradient and predictors for stepwise resistance escalation of carbapenem-susceptible, carbapenem-resistant, and difficult-to-treat resistantFrontiers in cellular and infection microbiology · 2026Article
- A broad-host-range inhalable phage cocktail for treatment of multidrug-resistantFrontiers in cellular and infection microbiology · 2026Article
- Clinical Risk Factors and Outcomes of Carbapenem-Resistant PInfection and drug resistance · 2026Article
- Whole-genome sequencing reveals resistance mechanisms and molecular epidemiology of carbapenem-resistant Pseudomonas aeruginosa bloodstream infections.BMC microbiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bloodstream infections (BSIs) caused by multidrug resistant Pseudomonas aeruginosa (MDRPA) and carbapenem resistant Pseudomonas aeruginosa (CRPA) accounted for high morbidity and mortality. This retrospective cohort study aimed to determine risk factors for MDRPA and CRPA BSIs by examining both clinical and laboratory data of inpatients with MDRPA and CRPA BSIs at two tertiary care hospitals in 2017-2021. Generalized linear mixed models were used to identify risk factors for MDRPA and CRPA BSIs. Factors significantly associated with both MDRPA BSIs and CRPA BSIs included central venous catheter, invasive ventilation including duration of use, urinary catheterization, gastric tube insertion, vancomycin use including quantity of usage, imipenem use including quantity of usage, and tigecycline use. Respiratory infection [adjusted odds ratio (aOR) 2.10, 95% confidence interval (95% CI) 1.00-4.42; P = 0.049] was identified as an independent risk factor for MDRPA BSIs. For CRPA BSIs, independent risk factors included the use of invasive ventilation [aOR 2.82, 95% CI 1.36-5.84; P = 0.005] and a history of tigecycline use [aOR 3.34, 95% CI 1.16-9.58; P = 0.025]. Conversely, circulatory system diseases [aOR 0.41, 95% CI 0.22-0.77; P = 0.006] and quantity of piperacillin-tazobactam use [aOR 0.83, 95% CI 0.72-0.96; P = 0.013] were identified as independent protective factors for CRPA BSIs. Inpatients with respiratory infection, invasive ventilation and a history of tigecycline use are at higher risk of MDRPA and CRPA BSIs. More prudent clinical interventions and antimicrobial therapy should be implemented to inpatients with these factors to prevent and control MDRPA and CRPA BSIs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.